A major academy intended to train radiologists and imaging professionals has been announced in Wales.
£3.4 million of funding has been invested in the project by the Welsh government
And the new National Imaging Academy for Wales will be based in Pencoed, Bridgend.
It is hoped that it will be fully operational by the mid-point of 2018.
Health Secretary Vaughan Gething announced the plan, indicating that the academy will "play an important role" in the training of radiologists, increasing... Readmore
A new treatment for rheumatoid arthritis could be made available on the NHS in the foreseeable future.
Regulators ruled Eli Lilly’s Olumiant to be cost-effective meaning that some patients could benefit from the treatment in the coming months.
Draft guidelines by the National Institute for Health and Care Excellence recommend Olumiant (baricitinib) as an option for treating severe active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with conventional... Readmore
Scientists in Wales have revealed that the first ever artificial heart pump in Britain is nearing real world functionality.
Swansea University's Institute of Life Science indicates that the pump will be ready for usage on patients in the foreseeable future.
Clinical trials are due to begin in late 2018 with the aim of a full rollout before the end of 2020.
The pump can be implanted into a heart experiencing difficulties, with researchers stating that a decade of usage will be possible for each... Readmore
Onzima Ventures has announced the conditional acquisition of the remaining 51% of the issued shares of N4 Pharma Limited, effectively taking over the firm.
Consideration for the acquisition will be satisfied by the issue of 4,510,800 New Ordinary Shares and 4,591,400 Deferred Consideration Shares.
The Company has also conditionally raised £1.5 million (gross) by way of a placing of 21,428,571 New Ordinary Shares at 7p per share .
This will be utilised in order to fund development of additional... Readmore
Polyphor Ltd has the completion of a CHF40 million private placement.
Exisiting Polyphor investors contributed to 98% of the financing.
Polyphor is a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases.
The proceeds will be used to finance the Pharma business unit, and particularly the pivotal registration programme of the antibiotic Murepavadin (POL7080) against... Readmore
New resources are being made available to employers, training providers and employment professionals to help alleviate London’s social care skills shortages.
Ambition London, funded by JP Morgan Chase Foundation, has authored two new toolkits.
These are intended to promote skills-sharing and tackle common misconceptions of careers in both the health and social care sectors.
It is known that health and adult social care sectors face an acute shortage of skilled workers with too few entrants,... Readmore
Medical gadgets have been a notable and increasingly prominent addition to the health landscape in the last few years.
Yet despite the benefits of such technology there is currently a distinct lack of legislation and regulation related to them.
In the United States, legislators are currently tackling this issue, with the Obama administration addressing the paucity of guidance for manufacturers of such devices.
It is well known among American government experts that the federal patient privacy... Readmore
Two studies presented at the UK Breast Cancer Research Symposium suggest that research into oestrogen receptors may be critical in treating breast cancer.
It is believed that understanding this may be key to explaining why some forms of breast cancer do not respond adequately to treatment.
The research has already been praised by healthcare experts as groundbreaking, and it is hoped that it will significantly inform the scientific response to the disease going forward.
In the first study, scientists... Readmore
The Royal College of physicians has questioned the existing NHS position over e-cigarettes.
At present, British doctors are only able to prescribe e-cigarettes if they have been specifically licensed as an aid to quit smoking.
This is currently strictly regulated, but some doctors believe that the distribution of e-cigarettes within the health service should be loosened.
Sales of e-cigarettes have been rising steadily since the first went on sale in 2007 in the UK.
They have already displaced... Readmore
Scientists in Britain have begun work on testing tumours from children with cancer, in the hope that this will ultimately provide younger patients with access to new and more personalised medicines.
It's also believe d that this body of work can help improve survival rates from the deadly condition, as researchers begin to get to grips with the killer disease.
The new test analyses changes in 81 different cancer genes.
It is hoped that the research will ultimately lead to what scientists describe... Readmore
A new device for managing sickle cell disease could save the NHS in the region of £13 million annually.
The National Institute for Health and Care Excellence (NICE) has already recommended the device, believing that it will make sickle cell disease easier to manage.
In its latest guidance, NICE recommends the Spectra Optia Apheresis System for red blood exchange in patients with sickle cell disease who require regular transfusion.
Although sickle cell disease is not a particularly well-known... Readmore
Technology continues to produce new innovations in the field of cancer research, prevention and treatment, and a new test is set to revolutionise the niche still further.
By the end of the decade, it is predicted that a 10-minute test which enables cancer to be detected will be available in the UK.
Patients who purchase the "liquid biopsy" would be required to send a small amount of saliva off to a laboratory.
Scientists can then analyse the saliva provided by the patient in order to ascertain... Readmore